作者
Ciara A. Murray,Clare D’Arcy,Giuseppe Gullo,Louise Flanagan,Cecily Quinn
摘要
To the Editor.—We welcome the recently published American Society of Clinical Oncology (ASCO) and College of American Pathologists (CAP) clinical practice guideline focused update for human epidermal growth factor receptor 2 (HER2) testing in invasive breast carcinoma.1The 2013 ASCO/CAP guideline2 addressed concerns that the 2007 diagnostic requirements3 for HER2 positivity were too rigid, potentially excluding patients who would have been deemed eligible for targeted therapy in the initial trastuzumab trial.4,5 In addition to reducing the threshold for positive and equivocal HER2 status on immunohistochemistry (IHC), the HER2:chromosome enumeration probe 17 (CEP17) ratio used to define a positive in situ hybridization (ISH) result decreased from ≥ 2.2 to ≥ 2 irrespective of HER2 copy number. Tumors with a ratio < 2 were positive if the copy number was ≥ 6 and equivocal if copy number was ≥ 4 and < 6.2 Recent re-evaluation of the interpretations of the HER2 fluorescent in situ hybridization (FISH) assays from Breast Cancer International Research Group clinical trials showed significant benefit from trastuzumab therapy only in patients with a tumor HER2:CEP17 ratio ≥ 2.0 and copy number ≥ 4.0.6 This profile is considered definitively positive in the 2018 update, which incorporates IHC and additional ISH cell counting to define HER2 status in the less common ISH patterns. Specifically, tumors with ratio ≥ 2.0 and copy number < 4.0 are negative unless IHC 3+. Tumors with ratio < 2.0 and copy number ≥ 6.0 are positive if IHC 3+ or IHC 2+ and the ISH result is confirmed by an additional observer. Equivocal cases with ratio < 2.0 and copy number ≥ 4.0 and < 6.0 are negative unless IHC 3+.1This study evaluated the impact of the changes in HER2 status categorization on a series of 1,044 tumors with equivocal HER2 IHC further tested using reflexive dual-probe HER2:CEP17 FISH methodology at St Vincent's University Hospital, Dublin, from 2014 to 2016. Specimens came from breast core biopsies, surgical excisions, and biopsies of metastatic sites and were identified from the histopathology database at St Vincent's University Hospital. The methods used were described previously by our group.7 FISH results were categorized using the scoring thresholds and definitions of the 2007, 2013, and 2018 ASCO/CAP guidelines,1–3 and the final diagnostic categories were compared.The application of the 2007 guideline for FISH-tested tumors revealed 112 (10.7%) positive, 814 (78.0%) negative, and 118 (11.3%) borderline (equivocal) tumors. Classification of the same tumors by the 2013 guideline elicited 182 (17.4%) positive, 824 (79.0%) negative, and 38 (3.6%) equivocal tumors. Categorization according to the 2018 update resulted in 107 (10.2%) positive, 937 (89.8%) negative, and no equivocal tumors. The relative distribution of HER2 FISH results is summarized in the Table.In this series of FISH-tested tumors, we observed an increase in positive tumors (17.4% v 10.7%) using 2013 criteria compared with 2007 criteria, identifying an additional 70 patients (6.7%) who met the eligibility criteria for HER2-targeted therapy.2,3 Applying the 2018 guideline,1 75 tumors (7.1% of the series) defined as positive applying 2013 criteria were recategorized as negative because of copy number < 4 with a ratio ≥ 2. These tumors were equivocal (45) and positive (30) when applying the 2007 guideline. The percentage of FISH-positive tumors (10.2%) according to 2018 criteria is similar to that observed using 2007 standards (10.7%), with an altered composition. The 107 tumors that were positive according to 2018 were positive (83), equivocal (23), and negative (1) using the 2007 guideline. These tumors were all positive according to 2013 criteria. Thirty patients (2.9%) with tumors positive by both 2007 and 2013 guidelines would no longer be candidates for HER2-targeted treatment. The recommendations regarding HER2 copy number ≥ 6 and HER2:CEP17 < 2.0 minimally affects our cohort, with only one tumor meeting this criterion for positivity, similar to other studies.8,9Our experience suggests that the 2018 update heralds a potential change in therapeutic options for a significant number of patients, with 2.9% of FISH-positive tumors according to 2007 and 2013 guidelines now categorized as HER2 negative.